On June 17, 2025, Regeneron Pharmaceuticals, Inc. (“Regeneron”) filed another complaint against Amgen Inc. (“Amgen”) under the BPCIA, alleging that Amgen’s aflibercept biosimilar, PAVBLU®, infringes U.S. Patent No. 12,331,099...more
6/20/2025
/ Amgen ,
Biosimilars ,
BPCIA ,
Hatch-Waxman ,
Injunctive Relief ,
Multidistrict Litigation ,
Patent Infringement ,
Patent Litigation ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Regeneron
On April 22, 2025, the U.S. District Court for the Northern District of West Virginia entered a Stipulation and Order Vacating Permanent Injunction and Dismissing All Claims and Counterclaims with Prejudice in In re:...more
4/29/2025
/ Biocon ,
Biosimilars ,
BPCIA ,
Dismissal With Prejudice ,
FDA Approval ,
Hatch-Waxman ,
Multidistrict Litigation ,
Mylan Pharmaceuticals ,
Patent Litigation ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Regeneron ,
Settlement Agreements